| Document |
Document Title |
|
WO/2022/066774A1 |
This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.
|
|
WO/2022/067114A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2022/059684A1 |
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a p...
|
|
WO/2022/056045A1 |
The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmace...
|
|
WO/2022/051979A1 |
A method for synthesizing a key intermediate compound 1 of fexuprazan, which is a potassium ion competitive blocker. The method comprises using 2,4-difluorobenzylamine as a raw material, and sequentially conducting condensation reaction,...
|
|
WO/2022/051286A1 |
The present disclosure includes compounds, compositions, and methods for preventing or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise ...
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2022/044037A1 |
The present invention provides an improved process for the preparation of upadacitinib of intermediate of formula II by reacting formula B with Grignard reagent in presence of an Iron catalyst.
|
|
WO/2022/040070A1 |
The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential tre...
|
|
WO/2022/040377A1 |
The present disclosure relates to methods of preparing compounds of Formula (VII) and salts thereof, and relates to compounds and combinations useful for the preparation. The present disclosure also relates to compounds being prepared by...
|
|
WO/2022/038166A1 |
The present invention relates to a synthetic process for amide coupling between a trihaloketone and an electron poor nucleophile, amenable to large scale synthesis, in particular, through a catalytic process.
|
|
WO/2022/036018A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound ...
|
|
WO/2022/032829A1 |
A spike protein receptor binding domain nanogel. The nanogel is obtained by means of chemically cross-linking a viral spike protein receptor binding domain and a cross-linking molecule represented by formula I. The described nanogel can ...
|
|
WO/2022/035904A1 |
Described herein are chlorpromazine, methods for making such compounds, and the use of such compounds in the treatment of cancer, an inflammatory disease or condition or neurodegenerative diseases, such as Parkinson's disease, Alzheimer'...
|
|
WO/2022/029805A1 |
The present invention relates to an improved highly efficient and economic process for large-scale production of Nintedanib and pharmaceutically acceptable salt thereof. The present invention also relates to a single step process that fo...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/021841A1 |
Disclosed are a novel coronavirus main protease inhibitor, and a preparation method therefor and the use thereof. Specifically provided are a compound represented by formula (I), a pharmaceutically acceptable salt, a stereoisomer, an opt...
|
|
WO/2022/022448A1 |
The present invention belongs to the pharmaceutical field. Specifically, the present invention relates to a neuraminidase inhibitor compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a ...
|
|
WO/2022/023839A1 |
This invention relates to the preparation of novel substituted acetamides of formula la-c and their use as anticonvulsants (I) a) R=Ph, R1=Me; b) R=Ph, R1=i-Pr; c) R=EtO, R1=Et.
|
|
WO/2022/018072A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2022/020242A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound ...
|
|
WO/2022/013565A1 |
The present invention relates to a co-crystal consisting essentially of curcumin and a co-crystal former, wherein the co-crystal former is a combination of nicotinamide and isonicotinamide, or wherein the co-crystal former is proline. Th...
|
|
WO/2022/016195A1 |
Provided herein are processes and intermediates useful for the preparation of certain compounds, including a compound of formula 21 or formula 22 or a pharmaceutically acceptable salt of either.
|
|
WO/2022/012481A1 |
Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.
|
|
WO/2022/007769A1 |
The present invention relates to a pyrrolidine amide derivative salt and the use thereof. The present invention further relates to a pharmaceutical composition containing the salt, and the use of the salt or the pharmaceutical compositio...
|
|
WO/2022/011084A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2022/008477A1 |
The present invention relates to 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro- pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity Formula (I) to processes of preparation of such compounds, ...
|
|
WO/2022/008975A1 |
Imide-linked polymeric photoinitiators and compositions useful in the preparation of such polymeric photoinitiators and to the use of these polymers in, e.g., UV curable adhesives, UV curable coating compositions and UV curable encapsula...
|
|
WO/2022/006192A1 |
The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological ...
|
|
WO/2022/000443A1 |
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
|
|
WO/2022/001649A1 |
A preparation method for α-ethyl-2-oxo-1-pyrrolidine acetate, and in particular, significantly improving reaction yield and product purity by optimizing a post-treatment process.
|
|
WO/2022/003405A1 |
An industrial scale telescopic process for preparing (2S)-1-[N-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarb
onitrile (Vildagliptin) of formula:, comprising: (a) reacting the compound of formula: with an excess of a compound of form...
|
|
WO/2021/262627A1 |
Provided herein are methods of treating certain cancers comprising administering to the subject in need there of an effective amount of a compound of Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wher...
|
|
WO/2021/262483A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present inven...
|
|
WO/2021/262541A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present d...
|
|
WO/2021/260232A1 |
The present invention concerns a method for the preparation of an alkyne-linker-payload construct of structure Q-L-C (O)-NR3-D (1), comprising reacting (i) an alkyne compound of structure Q-L- C(O)-X (2), wherein Q is an alkyne moiety se...
|
|
WO/2021/260721A1 |
The present invention relates to novel, economical processes for the preparation of enantiomerically pure Brivaracetam of Formula I having 99-100% diastereomeric excess (de) from its (R)-lactone intermediate that is (4R)-4-propyldihydrof...
|
|
WO/2021/253306A1 |
A method for preparing DL-proline, comprising the following steps: mixing L-proline and glacial acetic acid, stirring and raising the temperature to 60-75°C, continuing to maintain the temperature and stir for 2-6 hours and then distill...
|
|
WO/2021/253162A1 |
Provided is a preparation method for brivaracetam. The method has a synthetic route as shown below. The preparation method for the brivaracetam is simple, economical, environmentally friendly and suitable for industrialization.
|
|
WO/2021/252644A1 |
The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provid...
|
|
WO/2021/250355A1 |
The present invention relates to a composition for battery electrodes in which at least one solvent is a composition comprising between 80 and 95 % by mass of N-methylpyrrolidone (NMP).
|
|
WO/2021/251086A1 |
A first problem addressed by the present invention is to provide an active-ray-sensitive or radiation-sensitive resin composition with which a pattern having a favorable form can be obtained. Further, a second problem addressed by the pr...
|
|
WO/2021/250648A1 |
The invention relates to compounds of Formula (I'') wherein R, R1, R2, R3, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient b...
|
|
WO/2021/250174A1 |
The present invention relates to a process of manufacturing of (2S,5R)-5-(2- chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrro
lidine-2-carboxylic acid (1), including the preparation of (2S,5R)-methyl 5-(2-chlorophenyl)pyrroli...
|
|
WO/2021/245405A1 |
The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. ...
|
|
WO/2021/242753A1 |
Mitochondrial targeting compounds for the treatment of cancer and other disorders associated with mitochondrial function, including diabetes, autoimmune diseases, inflammatory diseases, cardiovascular diseases and neurodegenerative disea...
|
|
WO/2021/236449A1 |
Disclosed herein are p38a mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38a mitogen-activated protein kinase inhibitors.
|
|
WO/2021/234449A1 |
New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D, L-proline cocryst...
|
